Hemophagocytic Lymphohistiocytosis and Clostridium difficile Infection: A Diagnostic Dilemma

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition that often goes underdiagnosed because of broad and non-specific symptomatology, usually consisting of fever, hepatosplenomegaly, and multiorgan failure. This disorder can be driven by genetic components (primary) or acquired (secondary) causes related to infectious, autoimmune, or malignant processes. HLH pathogenesis derives from overactive and dysregulated immune system responses. This disorder often goes misdiagnosed because of similar clinical and laboratory findings to septicemia. Cases of HLH most commonly coexist with Epstein-Barr virus (EBV). Clostridium difficile (C. difficile) infection causing HLH has also rarely been described in the literature. A firm knowledge of HLH association with clostridial infection is essential to recognize. A presumed diagnosis of HLH in a decompensating patient may prompt the initiation of appropriate treatment earlier and improve clinical outcomes. We discuss the diagnostic and management difficulties associated with these concurrent conditions.

[1]  X. Chen,et al.  6-Mercaptopurine and Macrophage Activation Syndrome Case Report and Review of the Literature , 2022, Journal of pharmacy practice.

[2]  Yini Wang,et al.  Serum ferritin is a good indicator for predicting the efficacy of adult HLH induction therapy , 2022, Annals of medicine.

[3]  S. Cesaro,et al.  Emapalumab for adult and pediatric patients with hemophagocytic lymphohistiocytosis , 2021, Expert review of clinical pharmacology.

[4]  N. Berliner,et al.  Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. , 2019, Blood.

[5]  Mohammad Rahbar,et al.  Clostridium difficile infection: a review , 2018, Reviews in Medical Microbiology.

[6]  W. Wiktor-Jedrzejczak,et al.  Similar but not the same: Differential diagnosis of HLH and sepsis. , 2017, Critical reviews in oncology/hematology.

[7]  D. Giustini,et al.  Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review. , 2016, Blood reviews.

[8]  A. Filipovich,et al.  Pathogenesis of Hemophagocytic Lymphohistiocytosis. , 2015, Hematology/oncology clinics of North America.

[9]  A. Schram,et al.  How I treat hemophagocytic lymphohistiocytosis in the adult patient. , 2015, Blood.

[10]  A. Filipovich,et al.  Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab , 2013, Pediatric blood & cancer.

[11]  A. Filipovich,et al.  How I treat hemophagocytic lymphohistiocytosis. , 2011, Blood.

[12]  Suresh Kumar Nayudu,et al.  Hemophagocytic Lymphohistiocytosis in Association With Clostridium difficile Infection and Cutaneous T-Cell Lymphoma , 2011, World journal of oncology.

[13]  C. Kozinetz,et al.  Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality , 2011, Pediatric blood & cancer.

[14]  N. Rouphael,et al.  Infections associated with haemophagocytic syndrome , 2007, The Lancet Infectious Diseases.

[15]  M. Aricò,et al.  HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis , 2007, Pediatric blood & cancer.

[16]  T. Schenk,et al.  [Hemophagocytic lymphohistiocytosis in adults]. , 2016, Deutsche medizinische Wochenschrift.